Search Login Register

Vitelliform Macular Dystrophy Summary

Description: Autosomal dominant hereditary maculopathy with childhood-onset accumulation of LIPOFUSION in RETINAL PIGMENT EPITHELIUM. Affected individuals develop progressive central acuity loss, and distorted vision (METAMORPHOPSIA). It is associated with mutations in bestrophin, a chloride channel.

Also Known As: Adult-Onset Vitelliform Macular Dystrophy; Best Disease; Best Macular Dystrophy; Best Vitelliform Macular Dystrophy; Best's Disease Show All >>

Networked: 157 relevant articles (9 outcomes, 9 trials/studies) for this Disease

Key Drugs and Agents for Vitelliform Macular Dystrophy

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. bevacizumab : 5 outcomes in 10 results : FDA 2
  2. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor) : 1 outcome 1 study in 4 results : IBA
  3. 1-phenyl-3,3-dimethyltriazene (PDT) : 1 outcome in 4 results : IBA
  4. Triamcinolone Acetonide (Azmacort) : 1 outcome in 1 result : FDA 135 Generic
  5. Rifampin (Rifampicin) : 1 outcome in 1 result : FDA 13 Generic
  6. Dapsone : 1 outcome in 1 result : FDA 3
  7. densiron : 1 outcome in 1 result : IBA
  8. Retinaldehyde (Retinal) : 5 studies in 34 results : IBA
  9. Lipofuscin : 2 studies in 16 results : IBA
  10. Carbon Monoxide : 1 study in 2 results : IBA
Show All >>

Diseases Related to Vitelliform Macular Dystrophy

  1. Choroidal Neovascularization
  2. Pyoderma Gangrenosum
  3. Retinal Perforations
  4. Macular Degeneration (Age-Related Maculopathy)
  5. Vitelliform Macular Dystrophy
Show All >>

Key Therapies for Vitelliform Macular Dystrophy

Efficacy Chart >>
  1. Intravitreal Injections : 2 outcomes in 2 results
  2. Photochemotherapy (Photodynamic Therapy) : 1 outcome in 9 results
  3. Drug Therapy (Chemotherapy) : 5 results
  4. Radiotherapy : 2 results
  5. Lasers (Laser) : 2 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.